Chemotherapy Flashcards
1
Q
What is Ch14.18?
A
A human-mouse chimeric monoclonal antibody targeting GD2
2
Q
What are the toxicities of Ch14.18?
A
- pain
- tachycardia
- hypertension
- hypotension
- fever
- urticaria
3
Q
What are some less common toxicities of ch14.18?
A
- electrolyte abnormalities (HypoNa, hypoK)
- N/V
- diarrhea
- changes in pupillary reaction to light
4
Q
What is the biologic activity of ch14.18?
A
- complement dependent cytotoxicity
- antibody-dependent cytotoxicity (ADCC)
5
Q
What adjunctive therapies can augment the antibody-dependent cytotoxicity (ADCC) with ch14.18?
A
- GM-CSF
- IL-2
6
Q
Which antibody targets IL-6R?
A
Tocilizumab
7
Q
What is a complication of CAR T-cells? management?
A
Cytokine release syndrome (characterized by elevated ferritin). management = anti-IL6 (toci)
8
Q
what is inotuzumab?
A
anti-CD22 conjugated to calicheamicin
9
Q
side effects of inotuzumab?
A
increased incidence of VOD/SOS - particularly in patients who went to HSCT after
